Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | HTR6 | P50406 | 10/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | FABP4 | P15090 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.42 |
| ▸ | KIF18A | Q8NI77 | 1/20 | 0.41 |
| ▸ | MET | P08581 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30999723 | 0.88 | HTR6 (0.62) | TSHRHTR6NPSR1GAAHTT | |
| SCHEMBL6548765 | 0.86 | COMT (0.50) | ALDH1A1TSHRHTR6NPSR1GAA | |
| SCHEMBL10693393 | 0.77 | LDHA (0.63) | HTR6GAA | |
| SCHEMBL6548237 | 0.77 | HTR6 (0.49) | HTR6NPSR1GAAFABP4KMT2A | |
| SCHEMBL13185751 | 0.76 | ALDH1A1 (0.53) | ALDH1A1TSHRNPSR1GAAHTT | |
| SCHEMBL3174180 | 0.76 | ALDH1A1 (0.53) | ALDH1A1TSHRNPSR1GAAHTT | |
| SCHEMBL4880115 | 0.76 | LDHA (0.62) | ALDH1A1TSHRNPSR1GAAHTT | |
| SCHEMBL4573139 | 0.76 | ALDH1A1 (0.53) | ALDH1A1TSHRNPSR1GAAHTT | |
| SCHEMBL1339739 | 0.76 | ALDH1A1 (0.53) | ALDH1A1TSHRNPSR1GAAHTT | |
| SCHEMBL776706 | 0.75 | HTR6 (0.57) | TSHRHTR6GAAHTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1478361-A2 | ARYLSULFONE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 2004-11-24 | — | — | EP | disclosed |
| US-20030220325-A1 | Such as 1-(4-(phenylsulfonyl)-naphthyl)piperazine; for treating treating diseases related to 5-HT receptor; radiolabelling | PHARMACIA & UPJOHN COMPANY | 2003-11-27 | — | — | US | disclosed |
| WO-2003072558-A2 | ARYLSULFONE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 2003-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220325-A1 | Such as 1-(4-(phenylsulfonyl)-naphthyl)piperazine; for treating treating diseases related to 5-HT receptor; radiolabelling | HTR6, TPH1, HTR5A | ALDH1A1 593/4885TSHR 224/4885HTR6 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.